Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer by Thomassen, Mads et al.
Comparison of Gene Sets for Expression Profiling: Prediction
of Metastasis from Low-Malignant Breast Cancer
Mads Thomassen,1,4 Qihua Tan,1,4,5 Freyja Eiriksdottir,1,4 Martin Bak,2 Sren Cold,3
and Torben A. Kruse1,4
Abstract Purpose: In the low-risk group of breast cancer patients, a subgroup experiences metastatic
recurrence of the disease. The aim of this study was to examine the performance of gene sets,
developed mainly from high-risk tumors, in a group of low-malignant tumors.
Experimental Design: Twenty-six tumors from low-risk patients and 34 low-malignant
T2 tumors from patients with slightly higher risk have been examined by genome-wide gene
expression analysis. Nine prognostic gene sets were tested in this data set.
Results: A 32-gene profile (HUMAC32) that accurately predicts metastasis has previously
been developed from this data set. In the present study, six of the eight other gene sets have
prognostic power in the low-malignant patient group, whereas two have no prognostic value.
Despite a relatively small overlap between gene sets, there is high concordance of classification
of samples.This, together with analysis of functional gene groups, indicates that the same path-
ways may be represented by several of the gene sets. However, the results suggest that low-risk
patients may be classified more accurately with gene signatures developed especially for this
patient group.
Conclusion: Several gene sets, mainly developed in high-risk cancers, predict metastasis from
low-malignant cancer.
Breast cancer patients are classified into groups with high- or
low-risk of recurrence using a combination of clinical and
pathologic criteria. The high-risk group includes the majority
of patients, and they are offered adjuvant treatment; whereas
the low-risk patients are not offered treatment besides surgery,
according to treatment guidelines and risk criteria from the
Danish Breast Cancer Cooperative Group. However, a consid-
erable overtreatment occurs in the high-risk group, and
recurrence still occurs in the low-risk group.
Recently, promising results for improvement of risk assess-
ment, mainly in the high-risk group, have been obtained by
gene expression profiling of breast tumors. Different strategies
and platforms have been used to accomplish this. Genome-
wide gene expression analysis with long oligonucleotides or
Affymetrix chips has been used by several groups. A Dutch
group used a Rosetta chip with 60-mer oligonucleotides and
developed a 70-gene profile, which could predict development
of metastasis within 5 years among lymph node–negative
patients with higher accuracy than the classic clinical-pathologic
methods (1). The 70-gene signature has been validated with
similar results by the same group on a cohort of patients,
including patients with lymph node–positive disease (2, 3).
Another group, also from the Netherlands, did a similar study
with the Affymetrix platform and found a 76-gene profile for
prediction of distant metastasis within 5 years in patients who
had no adjuvant treatment and no lymph node involvement of
the disease (4, 5). Furthermore, by use of Affymetrix chips, a
Swedish group has developed a 64-gene signature classifying
patients into three risk groups (6). These studies have mainly
addressed the overtreatment in the high-risk group, and it has
been possible to classify a considerable group of the non-
metastatic tumors correctly although having a high sensitivity.
A different approach has been used by Ramaswamy et al.
who compared the expression profiles from primary tumors
and nonmatched metastases from several different tissues and
identified a 17-gene profile characteristic for metastasis but also
present in a subset of primary tumors, suggesting prognostic
value of the 17 genes. The prognostic value of this signature
was confirmed in the data set from van’t Veer et al. (7). Chang
et al. (8) hypothesized that features of normal wound healing
might play an important role in cancer. They identified a core
serum response (CSR) profile and validated the prognostic
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performance of this on the data provided by van de Vijver et al.
(8, 9). Sotiriou et al. aimed at a more precise measure for
histologic grade and developed a 97-gene profile capable of
separation of a considerable fraction of grade 2 tumors as grade
1 or grade 3 like. This profile had also shown prognostic power
in several data sets (10).
Besides the genome-wide approaches, focused expression
analysis with real-time PCR on candidate genes has also been
used. A 21-gene profile was developed for paraffin-embedded
tissue and could predict development of metastasis within
a large cohort of tamoxifen-treated patients (11). In another
study, the expression of only three genes served as an
independent prognostic marker (12).
There is a need for these prognostic signatures to be tested on
independent data sets before they come into clinical use.
However, a general problem is that different platforms are used
and these can be difficult to compare.
Besides the overtreatment in the high-risk group, another
important issue is to identify women who would benefit from
a treatment they are not offered today. In the low-risk group
of patients, f10% of patients experience recurrence and a
significant proportion of these patients would probably benefit
from adjuvant treatment. The above-mentioned studies hardly
include any low-risk patients with metastatic outcome who did
not receive adjuvant therapy. Patients receiving adjuvant
treatment are less informative because treatment response will
bias outcome classification. We have previously developed a
32-gene profile (HUMAC32) that accurately predicts develop-
ment of metastasis in this group of patients (13). In this study,
we compare prediction of metastasis in the low-malignant
group by the HUMAC32 profile and the above-mentioned
prognostic gene sets mainly developed in higher risk cancers.
The study is designed with pairs of metastasizing and non-
metastasizing tumors matched according to classic prognostic
markers, demonstrating the independent information from the
classifiers. We have developed classification algorithms with the
gene sets on our data, reducing the effect of different platforms.
Materials andMethods
Patient’s samples. For a large cohort of breast cancer patients treated
in the county of Funen from 1982 to 1999, tumor biopsies have
routinely been collected. Because a very small fraction of low-risk
patients develop metastasis, a nested case-control design was applied.
Thirteen patients who fulfilled the Danish Breast Cancer Cooperative
Group low-risk criteria and developed metastasis and 13 matched
patients for whom no metastasis were detected at the end of follow up
were selected (the 26 tumors are called low-malignant T1 or low-risk
tumors). The Danish Breast Cancer Cooperative Group low-risk criteria
are essentially the same as the criteria defined at the 8th St. Gallen
Meeting in 2003 (ref. 14)6: node negative, T V 20 mm, grade = 1 if
ductal carcinoma (not otherwise specified), receptor positive, and
age z 35. In addition, a group of 17 low-malignant T2 tumors [node
negative, 20 mm < T V 50 mm, grade = 1 if ductal carcinoma (not
otherwise specified), receptor positive, and age z 35] from patients who
developed metastasis and 17 matched patients who did not develop
metastasis were included. This group did not fulfill the Danish Breast
Cancer Cooperative Group low-risk criteria because the tumor size
was 20 to 50 mm, but satisfied all other criteria (this group is called
low-malignant T2 tumors). The tumors were matched pair-wise
according to tumor type as well as year of surgery, tumor size, and
age as far as possible. None of the patients had received adjuvant
systemic therapy. The average follow up for nonmetastasizing patients
was 12.3 years. The study was approved by the regional ethical
committee of Southern Denmark.
Gene-expression analysis. RNA was purified from tumor biopsies
with Trizol followed by further purification and DNase treatment on
RNeasy micro columns (Qiagen). For gene expression analysis, a 29K
oligonucleotide chip with duplicate measurement of each gene was
used as previously described (15). The sequence of the 70 original
oligonucleotides reported by van’t Veer (1) was downloaded from
Rosetta Inpharmatics website,7 and identical oligonucleotides were
spotted on the chips. The same approach could not be used for the
other gene sets because of different length of targets. Labeled aRNA
was prepared from 500 ng RNA using the Ambion Amino Allyl
MessageAmpTM aRNA kit as previously described (15).
Data analysis. Identification of spot locations and quantification
was done using arrayWoRx software (Applied Precision). Raw intensity
data were normalized using the variance stabilization normalization
procedure (16), implemented in the R package vsn . The prediction of
outcome and development of a 32-gene classifier (HUMAC32) is
described elsewhere (13). Briefly, classification was done by leaving one
matched pair of tumors out and selecting genes with nearest shrunken
centroids method in R package pamr (17). The selected genes were
submitted to support vector machines (SVM; R package e1071) to build
a hyper plane to separate the training set (58 samples) with maximal
margin and to use to classify new samples in the testing set (two
samples; ref. 18). Cross-validation was done for all 30 pairs, a scheme
called 30 classifier scheme. The optimal classifier (HUMAC32) was
developed by applying nearest shrunken centroids method to the entire
data set. All mentioned R packages are implemented in the R-based
Bioconductor package.8
Genes from previously reported prognostic gene sets were annotated
to the 29K chip by gene bank accession numbers, Unigene ID, or gene
symbol. The different gene sets were submitted to SVM and classi-
fication done by leaving one matched pair of tumors out at a time and
cross-validation as described above, except that the gene set was fixed.
The output from SVM is probability of poor outcome for each tumor.
A probability cutoff of 0.5 was applied to all classifications to obtain
comparable results. Furthermore, mean values of probability of poor
outcome were plotted for the different classifiers to compare the
separation of samples.
Concordance between two given classifiers were calculated as the
fraction of samples classified as identical. The functional analyses of
gene sets were generated through the use of expression analysis
systematic explorer (19). The program uses Fishers exact test to
calculate the probability of randomly selecting the number of genes
present in a gene set with a certain function from the gene list
represented on the used chip. The P value is subsequently corrected for
multiple testing by the Bonferroni method. The overlap between gene
sets was investigated with Microsoft Access using the annotation from
the 29K chip.
Results
A 30-classifier scheme constituted by 30 slightly different
gene sets and algorithms was developed. With this 30-classifier
scheme, 24 metastases and 23 nonmetastases were classified
correctly of the 60 samples corresponding to 78% accuracy
(Fig. 1A).
6 http://www.dbcg.dk
7 http://rii.com
8 http://www.bioconductor.org
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The objective in the present study was to evaluate the
prognostic value of a series of other previously reported gene
sets identified with different approaches. Eight gene sets,
however, all of them not fully represented on the 29K chip,
were tested with the same SVM method, leave-one-pair-out-
cross-validation. All the genes from the 70-gene signature were
evaluated by measuring the gene expression with the 70
original oligonucleotide sequences reported by van’t Veer (1),
resulting in 75% accuracy (Fig. 1B). The 76-gene profile
consisted of 60 genes used for receptor-positive tumors and
16 genes for receptor-negative tumors (4). To classify the
present receptor-positive tumors, 46 of the 60 genes were
identified in the 29K oligonucleotide set. Classification resulted
in 75% accuracy (Fig. 1C). The 64 genes, reported by Pawitan
et al. (6), were represented by 50 oligonucleotides, and 68%
accuracy was shown (Fig. 1D). Part of this data set was also
used by Sortiriou et al. (10) for development of a 97-gene grade
predictor. Ninety-one of these genes were represented on the
29K chip, and the resulting accuracy was 73% (Fig. 1E). The
serum response gene set was represented as 252 genes,
minimally required for prognostic evaluation of data sets
obtained with Stanford and Rosetta chips, resulting in 70%
accuracy in the present data (Fig. 1F; ref. 9). Seventeen gene sets
reported by Ramaswamy et al. (7), of which one was not
represented on the chip, resulted in poor separation of samples
and only 45% accuracy (Fig. 1G).
Finally, two gene sets, developed for reverse transcription-
PCR (RT-PCR) analysis of candidate genes, were tested. A
Fig. 1. Testing of nine prognostic reporter sets. Probability of poor outcome is plotted versus sample number. A, HUMAC32; B, 70-gene set; C, 76-gene set; D, 64-gene
set; E, 97-gene set; F, CSR; G, 17-gene set; H, 21-gene set; I, 3-gene set.The metastasizing tumors are presented left to the dashed line, and tumors from patients in whom
no metastases were detected right to this line. Samples above the horizontal line (P = 0.5) are classified as having poor prognosis. Asterisks, low-risk tumors; triangles,T2
tumors. Panel A is reprinted with permission (13).
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21-gene set, of which 5 house keeping genes were omitted and
one gene was not represented on the chip, resulted in clear
sample separation and 73% accuracy (Fig. 1H). The three-gene
set had low prognostic power in the present data set (48%
accuracy; Fig. 1I). Likewise an intrinsic gene set from a
Norwegian study, done with a cDNA chip from Stanford
University (20), was tested and resulted in accuracy comparable
with a random distribution of the samples (data not shown).
To examine concordance of classification of different gene
sets, the classification results from Fig. 1 are summarized in
Table 1. Furthermore, instead of evaluating the performance of
the classifiers with the somewhat arbitrary probability cutoff
limit of 0.5, inspection of mean probability of poor outcome
may be more informative (Fig. 2).
It is often found that the overlap between gene sets,
identified by different groups for prediction of cancer outcome,
is minor. The overlap of the nine gene sets is shown in Table 2.
Instead of using the 30 different gene sets from the 30 classifier
scheme, the optimal gene set from the present data set,
HUMAC32, was included in this analysis. One gene, coding
for the FLJ23468 protein (also known as MLF1P), was present
in five gene sets (64-gene, CSR, 76-gene, 97-gene, and
HUMAC32). CCNE2 and PRC1 were present in four gene sets
and 11 genes (ANKT, H2AFZ, HEC, DC13, MKI67, MYBL2,
CDC2, MELK, IMAGE:4826434, ASPM , and BM039) were
present in three gene sets. The performance of these 14 genes
overlapping at least three classifiers was tested in the present
data set resulting in 70% accuracy (data not shown).
To determine the overlap in biological function of the gene
sets, a comparison analysis was done by functional annotation
of genes (Table 3). This analysis was done for the seven gene
sets obtained with genome wide chip analysis.
Discussion
We have analyzed a low-malignant group of breast cancer
patients of which approximately one half would not receive
adjuvant therapy today. Very few of these low-risk patients have
been examined in previous reports. This group of patients is
particularly difficult to examine because a very low proportion
experiences recurrence. The follow-up time needs to be very
long to observe the often late on-setting metastasis, and the
tumors are small causing low occurrence in tumor banks and
low RNA yield. Among the recurrences are a high proportion of
contralateral cancers, which are currently difficult to determine
as metastases or new cancers. In this study, distant and regional
metastases, which are also the most severe form of recurrence,
are used as end point. We have previously developed a
prognostic 30-classifier scheme accurately predicting metastasis
in this patient group (Fig. 1A; ref. 13).
In the present study, eight other prognostic gene sets are
examined. We have not been able to use the original algorithms
because the data have not been available or the platforms
have been so different that this would not be meaningful. For
this reason, the SVM procedure with leave-one-pair-out
cross-validation seems reasonable for testing these sets. The
30-classifier scheme had higher accuracy and better separation
of the samples than the other tested gene sets (Figs. 1 and 2).
This may be explained by lower power for the other classifiers,
developed for higher risk cancers, in the present cohort of lower
risk tumors. This is supported by inspection of the two different
risk groups in the present tumor set: T1 and T2 tumors. With
the 30-classifier scheme, 31% of the misclassified tumors are T1
tumors (4 of 13), whereas it is 43% (6 of 14) for 76-gene set,
50% (10 of 20) for 64-gene set, 50% (9 of 18) for CSR, and
40% (6 of 15) for the 70-gene set, respectively (Fig. 1). The
21-gene set had comparable performance with the 30-classifier
Table 1. Concordance of gene sets
30-classifier 70-gene set 76-gene set 64-gene set 97-gene set CSR (252) 17-gene set 21-gene set 3 gene set
30-classifier 0.93 0.80 0.85 0.88 0.82 0.43 0.85 0.38
70-gene set 0.83 0.85 0.92 0.82 0.50 0.82 0.45
76-gene set 0.88 0.85 0.85 0.50 0.78 0.45
64-gene 0.90 0.90 0.45 0.77 0.43
97-gene set 0.87 0.48 0.80 0.47
CSR (252) 0.45 0.73 0.50
17-gene set 0.45 0.55
21-gene set 0.40
3-gene set
NOTE: Concordance in defined as the fraction of samples with identical classification result.
Fig. 2. Mean probability of poor outcome. Mean probability of poor outcome
for low-risk T1 tumors and low-malignant T2 tumors for the metastasis and
nonmetastasis group, respectively. The x axis is set to a probability of
0.5 corresponding to a random distribution of the samples.
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scheme (27%, 4 of 15); however, this gene set was also
developed on lymph node–negative and estrogen receptor–
positive tumors. A crucial effect of receptor status on gene
expression profile has been shown (4). When inspecting
separation of samples, in terms of probability of poor outcome,
the same tendency that T1 tumors are separated better than T2
tumors with 21-gene and HUMAC32 gene sets compared with
the other gene sets is also observed (Fig. 2). The pair-wise
matching of samples according to currently used clinical and
pathologic prognostic markers may also explain the lower
performance of the classifiers developed in cohorts. Cohort
classifiers are trained to track the classic prognostic markers
because these are strongly biased in outcome groups, whereas
the present design enable examination of prognostic value
independent from these markers. Several other factors like
different platforms, incomplete gene representation on the
present chip, different diagnostic procedures, and different
sampling procedures may explain the higher accuracy of
the 30-classifier scheme. However, this would most likely not
change the misclassification rate and separation of samples
between T1 and T2 tumors in the present data. The lack
of prognostic power in the 17-gene profile reported by
Ramaswamy may be explained by the fact that this profile
was developed on cancers originating from six different tissues
possibly reflecting other metastatic mechanisms. The low
performance of the three-gene and 17-gene set, measured by
low accuracy of classification, was supported by low concor-
dance to the other gene set corresponding to a random
distribution of the samples (Table 1).
Taking the low overlap between the gene sets in consider-
ation (Table 2), the relatively high agreement of classification
between the gene sets (Table 1) may indicate that the same
underlying biological pathways are represented in the gene
sets. Indeed there are several overlaps in the functions of the
classifier genes, with cell cycle and cell proliferation being
the predominant gene ontology categories (Table 3). This is
supported by Fan et al. (21), who recently reported high
concordance of an intrinsic gene set with four other signatures.
Table 2. Overlap between gene sets
HUMAC32 70-gene set 76-gene set 64-gene set 97-gene set CSR 17-gene set 21-gene set 3-gene set
HUMAC32 8 2 5 13 2 0 0 0
70-gene set 2 3 8 3 0 1 0
76-gene set 1 4 1 0 0 0
64-gene set 12 3 0 1 0
97-gene set 8 0 5 0
CSR 1 1 0
17-gene set 0 0
21-gene set 0
3-gene set
Present on the 29K chip 32 70 55 50 91 252 16 15 3
NOTE: The original number of genes in the classifier is indicated in the name of the classifier, and the number of genes included in the present
analysis is given in the last row.
Table 3. Gene ontology annotation of gene sets
Gene ontology\reporter genes 64-gene set 70-gene set76-gene set97-gene set CSR HUMAC3217-gene set
35 50 58 83 275 22 16
Mitotic cell cycle 11 (0.000006) 7 (0.9) 8 (0.7) 41 (8e-37) 45 (2e-17) 8 (0.0002) 1
Cell cycle 13 (0.00008) 9 10 44 (1e-27) 58 (2e-13) 8 (0.03) 1
Cell proliferation 13 (0.006) 11 15 (0.4) 44 (2e-20) 66 (3e-10) 9 (0.05) 4
Mitosis 7 (0.0004) 2 2 27 (4e-29) 21 (0.00000001) 4 (0.3) 1
M phase of mitotic cell cycle 7 (0.0005) 2 2 27 (6e-29) 21 (2e-08) 4 (0.3) 1
Nuclear division 7 (0.002) 2 2 27 (2e-26) 21 (0.0000004) 4 (0.6) 1
M phase 7 (0.002) 2 3 28 (1e-27) 21 (0.000001) 4 (0.7) 1
Regulation of cell cycle 9 (0.003) 3 5 20 (2e-08) 32 (0.000006) 2
Regulation of mitosis 4 (0.02) 7 (0.00001) 8 (0.007)
Cell growth and/or maintenance 24 (0.003) 22 29 55 (6e-08) 113 (0.7) 12 6
Cellular process 29 (0.05) 28 38 62 (0.01) 149 16 10
Obsolete cellular component 8 (0.1) 2 6 17 (0.00006) 31 (0.0006) 1 1
DNA replication and chromosome cycle 5 (0.7) 5 4 19 (6e-13) 25 (4e-08) 3 1
Cell growth and/or maintenance 24 (0.003) 22 29 55 (6e-08) 113 (0.7) 12 6
Obsolete cellular component 8 (0.1) 2 6 17 (0.00006) 31 (0.0006) 1 1
Chromosome 4 4 4 13 (0.0004) 24 (0.0001) 2
NOTE: Genes were annotated by gene bank accession numbers and submitted to expression analysis systematic explorer. The number of genes,
recognized by expression analysis systematic explorer and included in this analysis, is indicated in the first row. Only gene ontology categories
significant for at least two gene sets (P V 0.05) are included for simplicity. P values are given in parentheses if different from 1.
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Unlike that study, we have done comparisons of all gene
sets mutually. Furthermore, we have developed classification
algorithms with SVM instead of adopting classification methods
from original studies, reducing the bias of different used
platforms.
TheMLF1P gene present in five of the seven gene sets deduced
from genome-wide expression profiling might be a potent
prognostic marker. High expression of this gene has been shown
in glioblastoma cell lines compared with normal brain tissue in
rat (22), and it binds to MLF1, a negative regulator of cell cycle
functioning upstream p53 (23). However, genes overlapping in
several classifiers may not be adequate classifier genes, because
14 genes overlapping in three or more classifiers had lower
performance than HUMAC32 in the present data. This may
indicate that HUMAC32 contain additional genes specific for
metastasizing from low-malignant cancer.
The clinical relevance of the current study is to prevent
metastasis among low-risk patients. Furthermore, the results
show a better classification of the patients with low-malignant
T2 tumors compared with the classic methods indicating a
potential to reduce the considerable overtreatment in this
group. Although only 26 low-risk tumors were included in this
study, it is actually the largest of its kind. The cohort study by
van de Vijver et al. (2) only included 22 patients of whom four
developed distant metastasis. In the study by Wang et al. (4), 14
low-risk patients, including three who developed metastasis,
were included in the testing sample set. The low-risk patients
used for development and validation of the 21-gene profile
were treated with tamoxifen, biasing the prognostic perfor-
mance of the signature (11). The present study shows consi-
derable prognostic power of 76-gene and 70-gene classifiers
among low-risk patients, thereby validating their performance
in this patient group.
The pair-wise matching of the present tumors corrects for
several factors which could bias the results. This include
diagnostic procedures that have changed over time e.g.,
implementation of more sensitive techniques for detection of
lymph node metastasis and receptor status. The sampling
methods that might have changed slightly and the storage time
at -80jC may have effect on the expression profiles, but these
biases are also minimized with the sample matching. Bias from
technical variation during purification and microarray proce-
dure of the samples has also been minimized by performing
simultaneous processing of the matched pairs.
Conclusion
In the low-risk group of breast cancer patients, a subgroup
experiences metastatic recurrence of the disease. Furthermore, a
considerable overtreatment occurs among patients with low-
malignant T2 tumors. We have developed a 30-classifier scheme
that accurately predicts metastasis in these groups. Six other
gene sets derived with different strategies were shown to have
prognostic power in the groups, whereas two had none. This,
together with functional analysis, indicates that the same
pathways may be represented in the gene sets. However, there
are indications suggesting that the low-malignant group may
be classified more precisely with classifiers, like HUMAC32,
developed especially for this group. Further studies with larger
cohorts of patients are required to address this question.
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